MSL & digital engagement

The high-value MSL moments, the digital cadences HCPs find acceptable (mean acceptability 1–5), and how it differs by setting and research activity.

After reviewing relevant data independently, to clarify questions ?or uncertainties30%i100
To discuss upcoming pipeline developments22%i100
To discuss complex treatment sequencing or decision-making20%i100
As a follow-up after I requested medical info19%i100
As a first introduction to new clinical or trial data17%i100
To explore safety, tolerability, or real-world experience in more depth16%i100
To explore how new data applies to specific patient types in my practice15%i100
I do not typically find 1:1 discussions with pharmaceutical company representatives necessary13%i100
To discuss clinical trial opportunities or research collaboration13%i100

Meaningful change updated only – Receiving updates only when there is practice changing evidence or a meaningful change to guidelines or standard of care5.88 / 7
Around major congresses only – Receiving updates only around major scientific congresses (pre- and post-congress), with minimal communication outside those periods5.25 / 7
Ad hoc – Receiving occasional ad hoc updates only when a new data release is highly relevant5.25 / 7
Monthly roundup – Receiving one monthly update summarizing all data relevant to my specialty4.59 / 7
Quarterly summary – Receiving a quarterly summary of the most important updates relevant to my specialty4.49 / 7
I generally prefer not to receive digital updates and instead access information independently when needed3.09 / 7

Whole sample

Academic

Community

Community

After reviewing relevant data independently, to clarify questions ?or uncertainties27%i91
To discuss upcoming pipeline developments21%i93
To discuss complex treatment sequencing or decision-making19%i95
As a follow-up after I requested medical info19%i96
As a first introduction to new clinical or trial data18%i106
To explore safety, tolerability, or real-world experience in more depth17%i102
To explore how new data applies to specific patient types in my practice15%i105
I do not typically find 1:1 discussions with pharmaceutical company representatives necessary15%i111

Academic

After reviewing relevant data independently, to clarify questions ?or uncertainties33%i111
To discuss upcoming pipeline developments24%i108
To discuss complex treatment sequencing or decision-making22%i107
As a follow-up after I requested medical info20%i105
To discuss clinical trial opportunities or research collaboration17%i126
As a first introduction to new clinical or trial data16%i95
To explore safety, tolerability, or real-world experience in more depth16%i98
To explore how new data applies to specific patient types in my practice14%i95

Research-active

Meaningful change updated only – Receiving updates only when there is practice changing evidence or a meaningful change to guidelines or standard of care5.85 / 7
Around major congresses only – Receiving updates only around major scientific congresses (pre- and post-congress), with minimal communication outside those periods5.26 / 7
Ad hoc – Receiving occasional ad hoc updates only when a new data release is highly relevant5.22 / 7
Monthly roundup – Receiving one monthly update summarizing all data relevant to my specialty4.52 / 7
Quarterly summary – Receiving a quarterly summary of the most important updates relevant to my specialty4.49 / 7
I generally prefer not to receive digital updates and instead access information independently when needed3.26 / 7

Not research-active

Meaningful change updated only – Receiving updates only when there is practice changing evidence or a meaningful change to guidelines or standard of care5.86 / 7
Around major congresses only – Receiving updates only around major scientific congresses (pre- and post-congress), with minimal communication outside those periods5.33 / 7
Ad hoc – Receiving occasional ad hoc updates only when a new data release is highly relevant5.26 / 7
Monthly roundup – Receiving one monthly update summarizing all data relevant to my specialty4.72 / 7
Quarterly summary – Receiving a quarterly summary of the most important updates relevant to my specialty4.60 / 7
I generally prefer not to receive digital updates and instead access information independently when needed2.94 / 7